THOUGHT OF THE DAY
Oral GLP-1 Launch Challenges Novo’s Market Leadership
Eli Lilly’s Foundayo has moved beyond regulatory approval into demonstrated commercial traction, generating $98 million in initial sales while prescriber adoption quadrupled to roughly 36,000 prescribers. That acceleration coincides with flat constant-currency sales for Novo Nordisk’s Wegovy and Ozempic injectables, marking a clear competitive shift toward convenient oral obesity treatments rather than a routine product-cycle development.
Signal: Favor LLY(Eli Lilly) on commercial momentum; treat NVO(Novo Nordisk) as an execution-risk short or underweight until its oral franchise closes the convenience and growth gap.
MACRO SUMMARY
Today's corporate news shows a two-speed economy. U.S. inflation has cooled, with core services inflation near 3.0%, flat July PPI, and sharply lower odds of a September Fed hike. That backdrop supports rate-sensitive growth assets and eases pressure on household financing, but long-term Treasury yields remain elevated because a $432 billion July deficit, heavy bond supply, and rising interest costs are forcing investors to demand greater fiscal compensation.
Consumer demand remains resilient but selective. COF(Capital One Financial) reported a 15% increase in card purchase volume, while AXP(American Express) raised its 2026 revenue-growth outlook after 9% billed-business growth. At the same time, value-oriented retailers and restaurants are outperforming higher-multiple concepts, while companies including BBWI(Bath & Body Works), EXPE(Expedia), and CHWY(Chewy) show weaker discretionary momentum. Businesses continue to face margin pressure from freight, tariffs, labor, memory chips, and energy, although pricing power and automation are separating stronger operators from weaker ones.
Credit conditions show a similar split. Large banks continue to report strong transaction activity and capital-markets revenue, but rising debt-funded AI investment is increasing sensitivity to financing costs and asset utilization. Companies such as CRWV(CoreWeave), SMCI(Super Micro Computer), and IREN(IREN Limited) are converting demand into large backlogs, yet their capital intensity, debt burdens, and negative cash flow expose the market to a sharper downside if AI spending or credit availability slows.
Forward Catalysts
- August 20: WMT(Walmart) earnings, with attention on consumer demand, freight costs, and operating margins.
- August 26: CRWD(CrowdStrike) earnings, a read-through on enterprise technology spending and cybersecurity demand.
- September 3: DELL(Dell Technologies) earnings, testing whether AI-server demand is converting into sustainable revenue and cash flow.
- September 29: MU(Micron Technology) earnings, with memory pricing, HBM demand, and Chinese competition central to the semiconductor cycle.
- Upcoming U.S. August CPI, PPI, and labor-market data, which will determine whether the recent decline in September Fed-hike expectations holds.
ACTIONABLE IDEAS
Actionable Ideas (Positive)
- LLY(Eli Lilly): Foundayo generated $98 million in initial sales and rapidly expanded its prescriber base, while Mounjaro and Zepbound continued to post strong growth. Action: Maintain or add to long exposure on pullbacks; the oral franchise is expanding Lilly’s obesity-market share and strengthening its competitive moat.
- CVS(CVS Health): CVS is combining transparent Foundayo and Zepbound pricing with $29 digital MinuteClinic access, cash-pay options, and a Medicare GLP-1 bridge program. Action: Use CVS as an access-and-distribution beneficiary of broader GLP-1 adoption, with potential upside from higher pharmacy traffic and integrated care monetization.
- V(Visa) and MA(Mastercard): Ackman’s new positions highlight the durability of payment-network economics as commerce becomes more digital and automated. Action: Favor the networks over lower-quality fintech exposure when seeking long-duration financial infrastructure.
Actionable Ideas (Negative)
- NVO(Novo Nordisk): Wegovy and Ozempic injectable sales stagnated at constant exchange rates as Lilly’s oral Foundayo gained rapid commercial traction. Action: Underweight or use rallies to reduce exposure; the core risk is not merely competition but a shift in treatment convenience that could pressure prescription growth, pricing, and margins.
- SMCI(Super Micro Computer) and CRWV(CoreWeave): Both companies report powerful AI demand but carry substantial capital requirements, debt exposure, and cash-flow risk. Action: Avoid chasing momentum; consider hedges around earnings and monitor backlog conversion, operating cash flow, and financing costs.
- WST(West Pharmaceutical Services): Strong GLP-1-linked demand supports the business, but a 37.1x forward P/E leaves little room for execution misses. Action: Do not initiate at elevated multiples; wait for a valuation reset or evidence that high-value-product growth remains durable.